Market Cap: $131.16B
VI
Vertex Pharmaceuticals Incorporated
VRTX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $131.16B
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…
Vertex Pharmaceuticals (Ticker: VRTX) is making headlines with its promising advancements in gene therapy, particularly with its latest Phase 3 clinical trial data for CASGEVY. This groundbreaking the…
Vertex Pharmaceuticals achieves a significant breakthrough in pediatric treatment for cystic fibrosis, as evidenced by recent Phase 3 trial data for their drug ALYFTREK. The results reveal that this t…
Vertex Pharmaceuticals (VRTX) faces an exciting opportunity as Health Canada initiates a review of suzetrigine, a groundbreaking non-opioid oral medication aimed at managing moderate to severe acute p…
Vertex Pharmaceuticals (Ticker: VRTX) sees a promising development with Germany’s GKV-Spitzenverband agreeing to reimburse its gene-edited therapy, CASGEVY. This approval is a significant milestone th…
Vertex Pharmaceuticals (Ticker: VRTX) has successfully negotiated a reimbursement agreement in Germany for its innovative gene therapy, CASGEVY, which targets sickle cell disease and beta thalassemia.…
Vertex Pharmaceuticals has achieved a significant milestone with the U.S. FDA approving the expanded use of its cystic fibrosis treatments, ALYFTREK and TRIKAFTA. This regulatory approval broadens pat…
Empowering Voices in Rare Disease Advocacy: CNBC Cares for the Overlooked In a remarkable push for change in the healthcare landscape, CNBC initiates "CNBC Cures," a comprehensive project focused on t…
Vertex Pharmaceuticals Advances in Kidney Disease Therapy Amid Market Volatility Vertex Pharmaceuticals has achieved a significant milestone by successfully completing a Phase 3 trial for povetacicept…
Vertex Pharmaceuticals Positions Itself for Expansion in Kidney Disease Therapy Vertex Pharmaceuticals Inc. is making significant strides in expanding its therapeutic portfolio, most recently through…
Vertex Pharmaceuticals Pioneers Innovation in Cystic Fibrosis Treatment Vertex Pharmaceuticals continues to solidify its position as a leader in the biopharmaceutical industry, particularly with its g…
Innovative Advocacy: The Esiason Legacy in Cystic Fibrosis Awareness In a stirring testimony at the recent CNBC Cures Summit, former NFL quarterback Boomer Esiason discusses the life-altering impact o…
Regulatory Dynamics in Rare Disease Innovation: The FDA's Critical Crossroads Recent discussions at the CNBC Cures Summit in New York City spotlight a growing apprehension regarding the efficacy of th…
Addressing Regulatory Challenges Amidst Innovations in Rare Disease Treatments In the current landscape of pharmaceutical innovation, the role of regulatory bodies in ensuring drug safety while foster…
Vertex Pharmaceuticals: Strengthening Confidence in Innovative Treatments Vertex Pharmaceuticals currently holds a prominent position in the biopharmaceutical sector, with a specific focus on deliveri…
Vertex Pharmaceuticals: Optimism Swells in Response to Innovative Pipeline Vertex Pharmaceuticals is currently at the forefront of attention in the biotechnology sector, fueled by an array of unusual…
Vertex Q4 revenue narrowly tops expectations, reinforcing core CF business Vertex Pharmaceuticals posts fourth-quarter revenue of $3.19 billion, narrowly exceeding the $3.18 billion FactSet consensus…
Macro calendar tightens cost outlook for drugmakers Labor and inflation reports this week tighten the operating outlook for drugmakers such as Vertex Pharmaceuticals, with U.S. payrolls on Wednesday a…
Data-driven week puts financing in the spotlight Vertex Pharmaceuticals is watching U.S. jobs and inflation data next week as a potential inflection point for the sector’s financing and R&D planning.…
### Revolutionizing Retail: Commercetools Cora and Vertex AI Commercetools demonstrates a significant advancement in e-commerce with the unveiling of Cora, an AI-driven shopping companion that leverag…
Vertex Pharmaceuticals: Pioneering Transformative Therapies in Cystic Fibrosis Vertex Pharmaceuticals continues to solidify its leadership in the biopharmaceutical industry through a focused strategy…
Vertex Pharmaceuticals Faces Mixed Analyst Sentiment Amid Competitive Landscape Vertex Pharmaceuticals, a leader in innovative therapies for cystic fibrosis and pain management, finds itself at a cros…
Vertex Pharmaceuticals' Strategic Focus Amidst Market Scrutiny Vertex Pharmaceuticals Inc. is currently at a pivotal point in its development strategy, especially in therapeutic areas such as cystic f…
Vertex Pharmaceuticals: Navigating the Evolving Biotech Landscape Vertex Pharmaceuticals is at the forefront of innovation within the biotechnology sector, particularly in the development of transform…
Vertex Pharmaceuticals Advances Gene Therapy for Sickle Cell Disease and Beta Thalassemia Vertex Pharmaceuticals Incorporated recently presents compelling clinical data on its gene therapy, Casgevy (e…